Having watched CYC for a number of years now I think the market is not factoring in the potential of this company. The US deal is excellent. Assited and funded into the giant US market by a leader who is already there. Almost fully de-risked the whole US venture. Then there is China and COPD. Must be a huge market. Timing between H1 and H2 revenue this year a non-issue. And add to that the CEO has signed onto lots of options that don't come into the money until the share price hits 90 cents in two years shows that the CEO has extreme confidence in CYC going forward.
I also expect that if/when the US entry occurs that CYC will become prime takeover material. Esp as they own the patents.
Toppped up in the low 50 cents for what I think is a great medium to longer term hold.
Sorry if this sounds overly positive but I think that the current share price only factors in the business as it stands today, without China or the US (or Ultralute - but I don't have a handle on metrics around that product yet.
CYC Price at posting:
50.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)